Patent number: 8202876
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
Type:
Grant
Filed:
September 24, 2007
Date of Patent:
June 19, 2012
Assignees:
IRM LLC, Novartis AG
Inventors:
Pamela Albaugh, Gregory B. Chopiuk, Qiang Ding, Shenlin Huang, Zuosheng Liu, Shifeng Pan, Pingda Ren, Xia Wang, Xing Wang, Yongping Xie, Chengzhi Zhang, Qiong Zhang, Guobao Zhang, Daniel Poon, Paul Renhowe, Martin Sendzik
Patent number: 8183248
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK1?1, JNK2?2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFR?, PKA, PKC?, PKD2, ROCK-II, Ros, Rsk1, SAPK2?, SAPK2?, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.
Type:
Grant
Filed:
May 10, 2006
Date of Patent:
May 22, 2012
Assignee:
IRM LLC
Inventors:
Advait Nagle, Nathanael Schiander Gray, Yi Liu, Pingda Ren, Taebo Sim, Shuli You
